Alnylam® Newsroom
WEBVisit our social channels to learn more about the innovative work we are doing at Alnylam.
Press Releases - Alnylam Pharmaceuticals, Inc.
WEBMay 7, 2024 · Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Alnylam Pharmaceuticals, Inc. (ALNY) Latest Stock News
WEBGet the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock news and headlines to help you in your trading and investing decisions.
Jun 24, 2024 Press Release for Alnylam - Alnylam …
WEBJun 24, 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year …
WEBFeb 15, 2024 · ALNY. − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 –. − Company...
Articles | Alnylam® Newsroom
WEBAug 15, 2024 · April 26, 2024 Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access and ... Alnylam's Head of Strategic Accounts discusses the rise of the Integrated Delivery Network and manufacturer relationship Read More ›
Alnylam Reports Additional Positive Interim Phase 1 Results for …
WEBOct 25, 2023 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase...
Alnylam Announces Preliminary* Fourth Quarter and Full Year …
WEBCAMBRIDGE, Mass., January 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global...
Alnylam Announces 2022 Product and Pipeline Goals and
WEBNov 19, 2021 · 2022 Product and Pipeline Goals. Alnylam intends to provide guidance on 2022 combined net product revenue for ONPATTRO®, GIVLAARI®, and OXLUMO® in association with its fourth quarter and full...
Dec 13, 2023 Press Release for Alnylam - Alnylam …
WEBDec 13, 2023 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.